Syntax Research, Inc. Moderna, Inc. Transaction History
Syntax Research, Inc.
- $148 Billion
- Q3 2024
A detailed history of Syntax Research, Inc. transactions in Moderna, Inc. stock. As of the latest transaction made, Syntax Research, Inc. holds 100 shares of MRNA stock, worth $4,076. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100Holding current value
$4,076% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding MRNA
# of Institutions
953Shares Held
241MCall Options Held
10.6MPut Options Held
18.7M-
Baillie Gifford & CO42.5MShares$1.73 Billion2.17% of portfolio
-
Vanguard Group Inc Valley Forge, PA40.2MShares$1.64 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY25.6MShares$1.04 Billion0.07% of portfolio
-
State Street Corp Boston, MA16.8MShares$687 Million0.05% of portfolio
-
Theleme Partners LLP London, X07.23MShares$295 Million28.47% of portfolio
About Moderna, Inc.
- Ticker MRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 391,200,000
- Market Cap $15.9B
- Description
- Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...